Elegance clinical trial: it was reported that vessel dissection occurred.The subject underwent treatment with the sterling balloon on (b)(6) 2022 as a part of the elegance clinical trial.The target lesion #001 was in the right proximal superficial femoral artery, right mid superficial femoral artery extending into right distal superficial femoral artery with 6 mm proximal reference vessel diameter and 6 mm distal reference vessel diameter with lesion length of 280 mm and 30% stenosis and was classified as transatlantic intersociety consensus (tasc) ii c lesion.Prior to target lesion treatment, the pre-treatment dilation was performed using 5 mm x 150 sterling pta balloon.Treatment of target lesion was performed by using 6 mmx 200 mm ranger drug coated balloon and implanting 6 mm x 120 mm and 6 mm x 80 mm eluvia drug eluting stents.Post treatment, 6 mm x 200 mm ranger drug coated balloon was used for post dilation and the final residual stenosis was noted to be 10%.On (b)(6) 2022, on the same day of index procedure, during the treatment of target lesion #001, dissection of grade c was noted.It was confirmed that dissection was due to 5 mm x 150 mm sterling pta balloon.In response to the event, bailout stent was placed.Post treatment, the final residual stenosis the target lesions were noted to be 10%.On the same day, the event was considered resolved and the subject was discharged on aspirin and clopidogrel.
|